• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 13, 2018

View Archived Issues

Regulatory front

The American Hospital Association and several other hospital groups are asking a federal court to order the Department of Health and Human Services to implement, within 30 days, a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs.  Read More

Financings

Proqr Therapeutics NV, of Leiden, the Netherlands, said it closed its underwritten public offering of 6.61 million ordinary shares at $15.75 each. Gross proceeds from the offering totaled approximately $104.1 million. Read More

Other news to note

Alivio Therapeutics Inc., a Boston-based affiliate of Puretech Health plc, secured a $3.3 million Department of Defense Technology/Therapeutic Development Award to advance ALV-107 for the treatment of interstitial cystitis/bladder pain syndrome with Hunner's lesions.  Read More

Appointments and advancements

Ironshore Pharmaceuticals Inc., of George Town, Cayman Islands, appointed Scott Evangelista president and chief operating officer. Read More

Clinical data for Sept. 12, 2018

Read More

Vital halts further work on liver failure cell therapy after latest phase III failure

Shares of Vital Therapies Inc. plunged 93 percent Wednesday after the San Diego-based firm reported another phase III miss with its ELAD cell-based therapy in acute forms of liver failure. Despite showing a numerical improvement in survival, the study, dubbed VTL-308, fell short of the primary endpoint seeking an improvement in overall survival in patients with severe alcoholic hepatitis through at least 91 days, as assessed using the Kaplan Meier statistical method. Read More

Streamlined IND process speeds Fosun Kite's CAR T candidate to clinic in China

HONG KONG – Shanghai-based Fosun Kite Biotechnology Co. Ltd. was granted approval from China's National Medical Products Administration (NMPA) to advance its gene therapy candidate, FKC-876, to clinical trials. Read More

Innovent joins CD47 race, chases first home-grown PD-1 approval in China

HONG KONG – Amid renewed interest in CD47 as an immuno-oncology target, Innovent Biologics Inc., of Suzhou, China, has received IND approval in China to start clinical trials of its monoclonal antibody (MAb), IBI-188. To further get ahead in the anti-CD47 race, Innovent will conduct clinical trials on IBI-188 at home and abroad simultaneously. Read More

Transparency campaign points to lack of compliance in clinical data reporting in Europe

LONDON – Half of all clinical trial sponsors in Europe have not complied with the requirement that results must be reported within 12 months of the study completing, according to research by transparency campaigner Ben Goldacre appearing Thursday in the British Medical Journal. Read More

New beginning for Narachi as Coda debuts with $19M series A

With "so many things going on in our biotechnology industry," Mike Narachi said he had his pick of opportunities following the shutdown of Orexigen Therapeutics Inc., whose obesity drug, Contrave (naltrexone HCl/bupropion HCl), went to Pernix Therapeutics Holdings Inc. at the end of July following bankruptcy proceedings. Read More

Gilead strikes $445M+ HBV deal with Precision Biosciences

A new strategic collaboration between Gilead Sciences Inc. and privately held Precision Biosciences Inc. will focus on developing therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision's Arcus genome editing technology. Precision is eligible for milestone payments of up to $445 million under the terms of the deal and, if successful, could see tiered royalties on sales reaching the midteens. The agreement could eventually lead Gilead to a potent new offering in HBV, where generic medicines have decimated the once-formidable revenues generated by Viread (tenofovir disoproxil fumarate), and sales of its newer medicine, Vemlidy (tenofovir alafenamide), have yet to gain the same traction. Read More

All JAKed up: Galapagos, Gilead shares rise on filgotinib phase III readout

DUBLIN – Shareholders in Galapagos NV enjoyed an 18 percent stock uptick Wednesday as filgotinib, the company's blockbuster-in-waiting, aced the first of three phase III trials in rheumatoid arthritis (RA) and whetted appetites for further phase III read-outs over the next nine months. Its partner, Gilead Sciences Inc., of Foster City, Calif., also traded up, by about 3 percent. That represents a combined valuation increase of about $3.5 billion across the two companies. Read More

Regulatory actions for Sept. 12, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe